This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
A Second Opinion: Discussing the approval of Senseonics implantable EverSense 365 CGM.
Ticker(s): SENS, MDT, ABT, DXCM, Beta BionicsWho's the expert?
Institution: Columbia University
- Physician-scientist with clinical and research focus in Type 2 Diabetes and related metabolic diseases.
- Board certified in Internal Medicine and fellowship in Endocrinology, Diabetes & Metabolism
- Research focus on the role of developmental pathways in the regulation of Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease, and the use of existing therapeutic agents in other scientific areas in novel applications to ameliorate obesity-induced complications including cancer.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
